Gastrointestinal symptom severity and progression in systemic sclerosis. (3rd March 2022)

• Record Type: Journal Article
• Authors: van Leeuwen, Nina M; Boonstra, Maaike; Fretheim, Håvard; Brunborg, Cathrine; Midtvedt, Øyvind; Garen, Torhild; Molberg, Øyvind; Huizinga, Tom W J; de Vries-Bouwstra, Jeska K; Hoffman-Vold, Anna-Maria
• Is Part Of: Rheumatology. Volume 61:Number 10(2022)
• Page Start: 4024
• Page End: 4034
• Publication Date: 2022-03-03
• Subjects: SSc -- gastrointestinal symptoms; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/keac118
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Objectives: To evaluate the severity and evolution of patient-reported gastrointestinal tract (GIT) symptoms in systemic sclerosis (SSc) patients, assess predictive factors for progression and determine the impact of standard of care treatment. Methods: SSc patients from the Leiden and Oslo cohorts were included. We assessed clinical data and patient-reported GIT symptoms measured by the validated University of California, Los-Angeles Gastrointestinal-tract (UCLA-GIT) score at baseline and annually. GIT severity and progression was determined. Logistic regression was applied to identify risk factors associated with baseline GIT symptom severity. Linear mixed-effect models were applied to assess progression in GIT symptom burden and to identify predictive factors. We repeated all analysis in patients with early disease (inception cohort) to exclude the effect of longstanding disease and increase insights in development of GIT symptom burden early in the disease course. Results: We included 834 SSc patients with baseline UCLA GIT scores, 454 from Leiden and 380 from Oslo. In the total cohort, 28% reported moderate-severe GIT symptoms at baseline, with increased risk for severity conferred by ACA, smoking and corticosteroid use, while use of calcium channel blockers appeared protective. In the inception cohort, 23% reported moderate-severe GIT symptoms at baseline, with increased risk for females and with smoking. Over time, symptom burden increased mainly for reflux/bloating. Female sex and ACA predicted GIT symptom progression. Conclusion: High GIT symptom burden is present early in SSc disease course. Both for prevalence and for progression of GIT symptom burden, female sex and smoking were identified as risk factors.